|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 重组脊髓灰质炎病毒用于治疗复发胶质母细胞瘤(英文)显示文摘Background The prognosis of patients with recurrent World Health Organization(WHO)grade IV malignant glioma is dismal,and there is currently no effective therapy.We conducted a dose-finding and toxicity study in this population of patients,evaluating convection-enhanced,intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera(PVSRIPO).PVSRIPO recognizes the poliovirus receptor CD155,which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment.Methods We enrolled consecutive adult patients who had recurrent supratentorial WHO grade IV malignant glioma,confirmed on histopathological testing,with measurable disease(contrast-enhancing tumor of≥1 cm and≤5.5 cm in the greatest dimension).The study evaluated seven doses,ranging between 107 and 1010 50%tissue-culture infectious doses(TCID50),first in a dose-escalation phase and then in a dose-expansion phase.Results From May 2012 through May 2017,a total of 61 patients were enrolled and received a dose of PVSRIPO.Dose level-1(5.0×107TCID50)was identified as the phase 2 dose.One dose-limiting toxic effect was observed;a patient in whom dose level 5(1010TCID50)was administered had a grade 4 intracranial hemorrhage immediately after the catheter was removed.To mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use,dose level 5 was deescalated to reach the phase 2 dose.In the dose-expansion phase,19%of the patients had a PVSRIPO-related adverse event of grade 3 or higher.Overall survival among the patients who received PVSRIPO reached a plateau of 21%(95%confidence interval,11 to 33)at 24 months that was sustained at 36 months.Conclusions Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential.The survival rate among patients who receivedPVSRIPO immunotherapy was higher at 24 and 36 months than the rate among historical controls. | Desjardins A Gromeier M Herndon JE 2nd Beaubier N Bolognesi DP Friedman AH Friedman HS McSherry F Muscat AM Nair S Peters KB Randazzo D Sampson JH Vlahovic G Harrison WT McLendon RE Ashley D Bigner DD | 2018 | 中华神经外科疾病研究杂志2018，17，4： | 2 |
| 2 | A comparison of performance-based measures of function in HIV-associated neurocognitive disorders显示文摘 | Gandhi NS Skolasky RL Peters KB | 2011 | J Neurovirol2011，17，2： | 1 |
| 3 | Phase 2 study of carbopl- atin, irinotecan, and bevaeizumab for recurrent glioblastoma after pro- gression on bevacizumab therapy显示文摘 | Reardon DA Desjardins A Peters KB | 2011 | Cancer2011，117，23： | 1 |
| 4 | Randomised study of endoscopic biliary endoprosthesis versus duct clearance for bile duct stones in high-risk patients显示文摘 | Chopra KB Peters RA O'Toole PA | 1996 | Lancet1996，348，： | 1 |
| 5 | Treatment of RecurrentIntracranial Hemangiopericytoma witli SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report显示文摘 | Peters KB McLendon R Morse MA | 2010 | Case Rep Oncol2010，3，1： | 1 |
| 6 | Effects of psychologic intervention on psoriasis:a preliminary report显示文摘 | Robert Z Peter B Knud KB | 1996 | J Am Academy of Dermatology1996，36，6： | 1 |
| 7 | Intragenic rearrangements in NRXN1 in three families with autism spectrum disorder,developmental delay,and speech delay[显示文摘 | Wisniowiecka KB Nesteruk M Peters SU | | 0，，05： | 1 |
| 8 | Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizum- ab therapy显示文摘 | Reardon DA Desjardins A Peters KB | 2011 | Cancer2011，117，23： | 1 |
| 9 | Bacterial activities in the sediment ofLake Velencei, Hungary显示文摘 | ANDREA KB PETER V GABOR C etal | 2003 | Hydrobiolo-gia2003，，13： | 1 |
| 10 | Treatment of recurrent intracranial hemangiopericytoma with SRC-Related tyrosine kinase targeted therapy:a case report显示文摘 | Peters KB McLendon R Morse MA | | 0，，： | 1 |
| 11 | Nipah virus: a recently emergent deadly paramyxovirus 显示文摘 | Chua KB Bellini WJ Rota PA Harcourt BH Tamin A Lam SK Ksiazek TG RoUin PE Zaki SR Shieh W Goldsmith CS Gubler DJ Roehrig JT Eaton B Gould AR Olson J Field H Daniels P Ling AE Peters CA Anderson IJ Mahy BW | 2000 | Science2000，288，5470： | 1 |
| 12 | Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma 显示文摘 | Martin K Peter F Sigrid KB | 2008 | Strahlenther Onkol2008，184，11： | 1 |
| 13 | Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab haive, recurrent glioblastoma显示文摘 | Reardon DA Desjardins A Peters KB | 2012 | J Neurooncol2012，107，1： | 1 |
| 14 | Vitamin Dproduction depends on ultraviolet-B dose but not on dose rate : arandomized controlled trial显示文摘 | Morten KB’Bogh Anne V Sehmeges Peter A | 2010 | Experimental Dermatology2010，20，： | 1 |
| 15 | Phase 2 study of car- boplatin, irinotecan, and bevacizumab for recurrent glioblastoma af- ter progression on bevaeizumab therapy 显示文摘 | Reardon DA Desjardins A Peters KB | 2011 | Cancer2011，117，23： | 1 |
| 16 | Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma 显示文摘 | Reardon DA Desjardins A Peters KB | 2012 | J Neurooncol2012，107，1： | 1 |
| 17 | Treatment of Recurrent Intracranial Hemangiopericytoma with SRC -Related Tyrosine Kinase Targeted Therapy: A Case Report 显示文摘 | Peters KB McLendon R Morse MA | 2010 | Case Rep Oneol2010，3，1： | 1 |
| 18 | Randomised study of endoscopic biliary endoprosthesis versus duet clearanee for bileduct stones in high-risk patients显示文摘 | Chopra KB Peters RA O'toole PA | 1996 | Laneet1996，348，： | 1 |
| 19 | Tirapazamine: a hypoxia-activated topoisomerase II poison显示文摘 | Peters KB Brown JM | 2002 | Cancer Res2002，62，18： | 1 |
| 20 | A review of VEGFI VEGFR -targeted therapeutics for recurrent glioblastoma显示文摘 | Reardon DA Turner S Peters KB | 2011 | J Natl Compr Canc Netw2011，9，41： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员